keyword
MENU ▼
Read by QxMD icon Read
search

urothelium cancer

keyword
https://www.readbyqxmd.com/read/28627636/formulation-and-characterization-of-egcg-for-the-treatment-of-superficial-bladder-cancer
#1
Katarzyna Dettlaff, Maciej Stawny, Magdalena Ogrodowczyk, Anna Jelińska, Waldemar Bednarski, Dorota Wątróbska-Świetlikowska, Rick W Keck, Omar A Khan, Ibrahim H Mostafa, Jerzy Jankun
In the United States, the annual incidence of bladder cancer is approximately 70,000 new cases, with a mortality rate of approximately 15,000/year. The most common subtype (70%) of bladder cancer is superficial, namely hte non-muscle invasive disease form limited to the urothelium. The rate of progression and recurrence is up to 40 and 70%, respectively. Urothelial cell carcinoma of the bladder is typically treated with transurethral resection. The cancerous cells can float onto the adjacent epithelium, increasing the risk of recurrence...
June 14, 2017: International Journal of Molecular Medicine
https://www.readbyqxmd.com/read/28588015/intravesical-bcg-induces-cd4-t-cell-expansion-in-an-immune-competent-model-of-bladder-cancer
#2
Max Kates, Thomas Nirschl, Nikolai A Sopko, Hotaka Matsui, Christina M Kochel, Leonardo O Reis, George J Netto, Mohammad Hoque, Noah M Hahn, David J McConkey, Alex S Baras, Charles G Drake, Trinity J Bivalacqua
Intravesical BCG immunotherapy is the standard of care in treating non-muscle invasive bladder cancer, yet its mechanism of action remains elusive.  Both innate and adaptive immune responses have been implicated in BCG activity. Although prior research has indirectly demonstrated the importance of T cells and shown a rise in CD4(+) T cells in bladder tissue after BCG, T-cell subpopulations have not been fully characterized.  We investigated the relationship between effector and regulatory T cells in an immune competent, clinically relevant rodent model of bladder cancer...
June 6, 2017: Cancer Immunology Research
https://www.readbyqxmd.com/read/28579283/optimizing-management-of-upper-tract-urothelial-carcinoma
#3
REVIEW
Matthew T Campbell, Amishi Y Shah, Surena F Matin, Arlene O Siefker-Radtke
Upper tract urothelial cancer (UTUC) is a rare cancer of the urothelium, comprising only a fraction of cases as compared to urothelial tumors of the bladder. As a result, systemic treatment approaches in bladder cancer are often applied to patients with UTUC. Given the anatomical location of these tumors, the age, the comorbid conditions of these patients with UTUC, and the need for radical nephroureterectomy for treatment, most patients have substantial impairment of renal reserve. There is growing evidence for the benefit of perioperative chemotherapy in this disease...
June 1, 2017: Urologic Oncology
https://www.readbyqxmd.com/read/28545586/disulfide-high-mobility-group-box-1-causes-bladder-pain-through-bladder-toll-like-receptor-4
#4
Fei Ma, Dimitrios E Kouzoukas, Katherine L Meyer-Siegler, Karin N Westlund, David E Hunt, Pedro L Vera
BACKGROUND: Bladder pain is a prominent symptom in several urological conditions (e.g. infection, painful bladder syndrome/interstitial cystitis, cancer). Understanding the mechanism of bladder pain is important, particularly when the pain is not accompanied by bladder pathology. Stimulation of protease activated receptor 4 (PAR4) in the urothelium results in bladder pain through release of urothelial high mobility group box-1 (HMGB1). HGMB1 has two functionally active redox states (disulfide and all-thiol) and it is not known which form elicits bladder pain...
May 25, 2017: BMC Physiology
https://www.readbyqxmd.com/read/28543959/epidemiology-of-urothelial-carcinoma
#5
REVIEW
Jun Miyazaki, Hiroyuki Nishiyama
The epithelium lining is defined as the mucosal surfaces of the renal collecting tubules, calyces and pelvis, as well as the ureter, bladder and urethra. The term "urothelium" is used to refer to these surfaces. Upper tract urothelial carcinoma is a rare subset of urothelial cancers with a poor prognosis. Urinary bladder cancer is the most common malignancy involving the urinary system. Upper tract urothelial carcinoma is more common in men than in women, with a male-to-female ratio of 2:1. The incidence of urinary bladder cancer is also higher in men...
May 21, 2017: International Journal of Urology: Official Journal of the Japanese Urological Association
https://www.readbyqxmd.com/read/28540814/lyso-thermosensitive-liposomal-doxorubicin-for-treatment-of-bladder-cancer
#6
Andrew S Mikhail, Ayele H Negussie, William F Pritchard, Dieter Haemmerich, David Woods, Ivane Bakhutashvili, Juan Esparza-Trujillo, Sam J Brancato, John Karanian, Piyush K Agarwal, Bradford J Wood
PURPOSE: To evaluate lyso-thermosensitive liposomal doxorubicin (LTLD, ThermoDox(®)) in combination with loco-regional mild hyperthermia (HT) for targeted drug delivery to the bladder wall and potential treatment of bladder cancer. MATERIAL AND METHODS: Porcine in vivo studies were performed with the following groups: (i) intravenous (IV) LTLD with hyperthermia (LTLD + HT); (ii) IV doxorubicin (DOX) with hyperthermia (IV DOX + HT) and (iii) IV LTLD without hyperthermia (LTLD - HT)...
May 10, 2017: International Journal of Hyperthermia
https://www.readbyqxmd.com/read/28506860/characterization-of-late-recurrence-after-radical-cystectomy-in-a-large-multicenter-cohort-of-bladder-cancer-patients
#7
Francesco Soria, Marco Moschini, Gregory J Wirth, Kilian M Gust, Tobias Klatte, Alberto Briganti, Paolo Gontero, Mohammad Abufaraj, Mehmet Özsoy, Pierre I Karakiewicz, Shahrokh F Shariat
OBJECTIVE: To investigate the characteristics and outcomes of late recurrence (LR) in bladder cancer (BCa) patients treated with radical cystectomy (RC) and to identify clinico-pathologic predictors of LR and post-recurrence survival. METHODS: This multicenter study included 1652 BCa patients. LR was defined as occurring more than 5 years after RC. Differences in post-recurrence overall survival according to the timing of disease recurrence and to the location of recurrence were calculated using the log rank test...
May 12, 2017: Urology
https://www.readbyqxmd.com/read/28500846/the-trophoblast-cell-surface-antigen-2-and-mir-125b-axis-in-urothelial-bladder-cancer
#8
Chiara Avellini, Caterina Licini, Raffaella Lazzarini, Rosaria Gesuita, Emanuela Guerra, Giovanni Tossetta, Clara Castellucci, Stefano Raffaele Giannubilo, Antonio Procopio, Saverio Alberti, Roberta Mazzucchelli, Fabiola Olivieri, Daniela Marzioni
Human trophoblast cell surface antigen 2 (Trop-2) is a 40-kDa transmembrane glycoprotein that was first identified as a marker of human trophoblast cells. Trop-2 acts on cell proliferation, adhesion, and migration by activating a number of intracellular signalling pathways. Elevated Trop-2 expression has been demonstrated in several types of cancer and correlated with aggressiveness and poor prognosis. Since no data are available on Trop-2 in bladder cancer (BC), the purpose of the study was to determine its levels in tissue specimens from normal individuals and patients with BC at different stages...
April 25, 2017: Oncotarget
https://www.readbyqxmd.com/read/28434947/effect-of-urinary-cytology-for-detecting-recurrence-in-remnant-urothelium-after-radical%C3%A2-cystectomy-insights-from-a-10-year-cytology-database
#9
Renate Pichler, Gennadi Tulchiner, Wilhelm Oberaigner, Georg Schaefer, Wolfgang Horninger, Andrea Brunner, Isabel Heidegger
BACKGROUND: We evaluated the diagnostic accuracy of urinary cytology (UCy) for detecting recurrence in the remnant urothelium (RRU) after radical cystectomy (RC) for urothelial cancer. PATIENTS AND METHODS: We conducted a 10-year retrospective analysis of a prospectively collected, single-center RC database comprising 177 patients who had undergone follow-up examinations at our department with ≥ 1 available postoperative UCy specimen. UCy specimens were classified using the Papanicolaou scheme...
March 30, 2017: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/28431768/is-there-room-for-luminal-basal-urothelial-cell-population-quantification
#10
G R Passos, J A Camargo, K L Ferrari, G C Franch, A E Nowill, L O Reis
PURPOSE: Three cell layers compose the urothelium: basal, intermediate and luminal ("umbrella cells") and different diseases might arise from different cell populations. The aim of this study is to analyze the quantification ability of such cell populations by using four different protocols. METHODS: Twenty male rats (Wistar) were randomized in four groups of five animals: scraping, enzymatic 30, 45 and 60minutes. The cells were isolated, analyzed by flow cytometer and data processed by BD FACSDIVA™ software...
April 18, 2017: Actas Urologicas Españolas
https://www.readbyqxmd.com/read/28428106/gata3-immunohistochemistry-in-urothelial-carcinoma-of-the-upper-urinary-tract-as-a-urothelial-marker-as-well-as-a-prognosticator
#11
Satoshi Inoue, Taichi Mizushima, Kazutoshi Fujita, Abdelrazak Meliti, Hiroki Ide, Seiji Yamaguchi, Hiroaki Fushimi, George J Netto, Norio Nonomura, Hiroshi Miyamoto
Immunohistochemistry of a transcription factor, GATA3, has been widely used as a promising urothelial marker in diagnostic surgical pathology practice. However, the expression status of GATA3 in upper urinary tract urothelial carcinomas (UUTUCs) and its prognostic significance have not been fully investigated. We immunohistochemically stained for GATA3 in 99 UUTUC samples and paired non-neoplastic urothelial tissues. GATA3 was positive in 51 [51.5%; 32 (32.3%) weak, 11 (11.1%) moderate, 8 (8.1%) strong] of 99 UUTUCs, which was significantly lower than in benign urothelium [79 (96...
April 17, 2017: Human Pathology
https://www.readbyqxmd.com/read/28419193/a-randomized-phase-ii-iii-study-of-cabazitaxel-versus-vinflunine-in-metastatic-or-locally-advanced-transitional-cell-carcinoma-of-the-urothelium-secavin
#12
J Bellmunt, J M Kerst, F Vázquez, R Morales-Barrera, E Grande, A Medina, Mªb González Graguera, G Rubio, U Anido, O Fernández Calvo, E González-Billalabeitia, Ajm Van den Eertwegh, E Pujol, J L Perez-Gracia, J L González Larriba, R Collado, M Los, S Maciá, R De Wit
BACKGROUND: Despite the advent of immunotherapy in urothelial cancer, there is still a need to find effective cytotoxic agents beyond first and second line. Vinflunine is the only treatment approved in this setting by the European Medicines Agency (EMA) and taxanes are also widely used in second line. Cabazitaxel is a taxane with activity in docetaxel-refractory cancers. A randomized study was conducted to compare its efficacy vs vinflunine. PATIENTS AND METHODS: This is a multicenter, randomized, open-label, phase II/III study, following a Simon's optimal method with stopping rules based on an interim futility analysis and a formal efficacy analysis at the end of the phase II...
April 13, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28415801/identification-of-long-non-coding-rnas-that-stimulate-cell-survival-in-bladder-cancer
#13
Aleksandra M Dudek, Sabrina J Boer, Nanda Boon, J Alfred Witjes, Lambertus A L M Kiemeney, Gerald W Verhaegh
For many years, research on the biology underlying bladder cancer focused on protein-coding genes which cover only about 3% of the human genome. Recently, it was discovered that a large part of the human genome is actively transcribed as long non-coding RNAs (lncRNAs). LncRNAs are master regulators of gene expression and several lncRNAs were shown to play a role in bladder cancer development and progression. Here, we analyzed lncRNA expression in muscle-invasive bladder cancer (MIBC) using the MiTranscriptome database of cancer lncRNA expression profiles, and we studied their function in bladder cancer-derived tumor cells...
May 23, 2017: Oncotarget
https://www.readbyqxmd.com/read/28403596/blue-light-cystoscopy-with-hexylaminolevulinate-our-7-years-experience
#14
Vito Lacetera, Ubaldo Cantoro, Lorenzo Montesi, Daniele Cantoro, Bernardo Cervelli, Antonio Cicetti, Giuliana Gabrielloni, Domenico Milella, Michele Montesi, Roberto Morcellini, Gianni Parri, Emilio Recanatini, Valerio Beatrici
AIM: The objective of the present study is to evaluate the diagnostic accuracy of hexylaminolevulinate (HAL) blue light cystoscopy compared with standard white light cystoscopy (WLC) in daily practice. MATERIALS AND METHODS: An observational, comparative, controlled (within patient) study was carried out at our Center. 61 consecutive patients with suspected or confirmed bladder cancer were recruited for the study from January 2008 until January 2015. Patients with suspected bladder cancer (positive cytology with negative WLC) or history of previous high-grade NMIBC or CIS were included in the study...
March 31, 2017: Archivio Italiano di Urologia, Andrologia
https://www.readbyqxmd.com/read/28373455/comparison-of-efficacy-of-adjuvant-mec-methotrexate-epirubicin-and-cisplatin-and-gc-gemcitabine-and-cisplatin-in-advanced-upper-tract-urothelial-carcinoma
#15
COMPARATIVE STUDY
Sheng-Chun Hung, Shian-Shiang Wang, Chun-Kuang Yang, Jian-Ri Li, Chen-Li Cheng, Yen-Chuan Ou, Hao-Chung Ho, Kun-Yuan Chiu, Chuan-Shu Chen
AIM: To evaluate the efficacy of methotrexate, epirubicin and cisplatin (MEC) or gemcitabine and cisplatin (GC) as adjuvant chemotherapy in advanced upper tract urothelium carcinoma (UTUC). PATIENTS AND METHODS: From 2002 January to 2008 December, a total of 70 patients with advanced UTUC received radical nephroureterctomy at our Institute with MEC and GC as adjuvant chemotherapy. Disease-free survival (DFS), cancer-specific survival (CSS) and overall survival (OS) among the two groups were evaluated...
April 2017: Anticancer Research
https://www.readbyqxmd.com/read/28367434/mediator-complex-subunit-med1-protein-expression-is-decreased-during-bladder-cancer-progression
#16
Niklas Klümper, Isabella Syring, Wenzel Vogel, Doris Schmidt, Stefan C Müller, Jörg Ellinger, Zaki Shaikhibrahim, Johannes Brägelmann, Sven Perner
INTRODUCTION: Bladder cancer (BCa) is among the most frequent cancer entities and relevantly contributes to cancer-associated deaths worldwide. The multi-protein Mediator complex is a central regulator of the transcriptional machinery of protein-coding genes and has been described to be altered in several malignancies. MED1, a subunit of the tail module, was described to negatively modulate expression of metastasis-related genes and to be downregulated in melanoma and lung cancer. In contrast, MED1 hyperactivity was described in breast and prostate cancer, likely due its function as a hub for nuclear hormone receptors...
2017: Frontiers in Medicine
https://www.readbyqxmd.com/read/28327458/nfatc1-expression-as-a-prognosticator-in-urothelial-carcinoma-of-the-upper-urinary-tract
#17
Takashi Kawahara, Satoshi Inoue, Kazutoshi Fujita, Taichi Mizushima, Hiroki Ide, Seiji Yamaguchi, Hiroaki Fushimi, Norio Nonomura, Hiroshi Miyamoto
We recently found that NFATc1, a member of the NFAT family and a key regulator of the immune response, could induce bladder carcinogenesis and cancer progression. In this study, we immunohistochemically stained for NFATc1 in upper urinary tract urothelial carcinoma (UUTUC) specimens and paired nonneoplastic urothelial tissues. NFATc1 was positive in 51 [52%; 40 (40%) weak (1+), 9 (9%) moderate (2+), and 2 (2%) strong (3+)] of 99 UUTUCs, which was significantly higher than in benign urothelium [30 (36%) of 83; 28 (34%) weak and 2 (2%) moderate] (0 vs 1+/2+/3+, P=...
June 2017: Translational Oncology
https://www.readbyqxmd.com/read/28257819/in%C3%A2-vitro-and-ex%C3%A2-vivo-permeability-studies-of-paclitaxel-and-doxorubicin-from-drug-eluting-biodegradable-ureteral-stents
#18
Alexandre A Barros, Carlos Oliveira, Rui L Reis, Estevão Lima, Ana Rita C Duarte
A drug-eluting biodegradable ureteral stent (BUS) has been developed as a new approach for the treatment of urothelial tumors of upper urinary tract cancer. In a previous work, this system has proven to be a good carrier for anticancer drugs as a potential effective and sustainable intravesical drug delivery system. BUS has revealed to reduce in 75% the viability of human urothelial cancer cells (T24) after 72 h of contact and demonstrated minimal cytotoxic effect on human umbilical vein endothelial cells (HUVECs) which were used as a control...
February 28, 2017: Journal of Pharmaceutical Sciences
https://www.readbyqxmd.com/read/28248032/-the-risk-of-bladder-cancer-in-patients-with-prostatic-hyperplasia-and-strategies-to-manage-this-combination
#19
Yu G Alyaev, A M Pshikhachev, A N Perekalina
The combination of bladder cancer with benign prostatic hyperplasia (BPH) occurs in 5-27% of cases. The link between these diseases has not yet been closely investigated. The main role in the pathogenesis of bladder cancer combined with BPH is played by the residual urine and prolonged exposure of urothelium to the urine carcinogens. The choice of surgical treatment modality for the combination of non-muscle invasive bladder cancer and BPH is still a matter of debate. There is no consensus on the safety and appropriateness of simultaneous transurethral resection of the bladder and prostate in these patients...
November 2016: Urologii︠a︡
https://www.readbyqxmd.com/read/28240746/epithelial-mesenchymal-transition-promotes-sox2-and-nanog-expression-in-bladder-cancer
#20
Toshiro Migita, Ayano Ueda, Tomokazu Ohishi, Megumi Hatano, Hiroyuki Seimiya, Shin-Ichiro Horiguchi, Fumitaka Koga, Futoshi Shibasaki
Bladder cancer is the most common malignant tumor of the urothelium and is classified into non-muscle-invasive bladder cancer (NMIBC) and muscle-invasive bladder cancer (MIBC). Stemness markers such as SOX2 and NANOG are frequently overexpressed in various aggressive cancers, including MIBC; epithelial-mesenchymal transition (EMT) has been proposed as a potential trigger of stemness in cancers. To determine whether cancer stemness is acquired via EMT in bladder cancer, we studied the effect of EMT on the expression of SOX2 and NANOG in bladder cancer cell lines...
February 27, 2017: Laboratory Investigation; a Journal of Technical Methods and Pathology
keyword
keyword
53999
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"